Volume 4, Issue 2 (9-2021)
2021, 4(2): 0-0 |
Back to browse issues page
Ethics code: IR.MEDILAM.REC.1400.017
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
nargesi S, rashkikemmak A, dolatshahi Z, mezginejad F, Norozi S. Economic evaluation of ivabradine in treatment of patients with heart failure: A systematic review. Journal title 2021; 4 (2)
URL: http://newresearch.medilam.ac.ir/article-1-1401-en.html
URL: http://newresearch.medilam.ac.ir/article-1-1401-en.html
Abstract: (1995 Views)
Although there have been many advances in the treatment of heart disease in recent decades, the prevalence of heart failure is increasing. The American Heart Association reports that about 7.3 percent of all deaths from heart disease are often due to heart failure. (1) Heart disease often leads to chronic heart failure, an incurable disease with severe and progressive fatigue. , Intolerance to exercise, fluid retention and shortness of breath are characterized (2).
Heart failure is one of the most common cardiovascular disorders and is considered as a chronic, progressive and debilitating disorder. Its prevalence increases with age, so that in the United States, about one percent of people over the age of 50 and about ten percent of the elderly over the age of 80 have heart failure. On the other hand, progress in treatment and surgery has caused patients who survive death from myocardial infarction to subsequently develop heart failure (3) Increasing trend of heart failure due to complications of infectious, inflammatory, vascular and valvular diseases Heart disease is also a major health problem and an epidemic in the United States, with 5 million people with heart failure in the United States, and about 500,000 new cases are added each year, and are expected in the next 30 years. Double the existing statistics (4) Research shows that the quality of life of heart failure patients is lower than the general population and also compared to other chronic patients. (5)
The US Food and Drug Administration (FDA) approved Corlanor, a generic drug called Ivabradine, in 2015 to reduce the severity of heart failure (chronic heart failure) in 2015. It is used in patients with symptoms of persistent heart failure (normal heart rate is at least 70 beats per minute).
Cost-effectiveness analysis of Ivabradine as a new strategy in the treatment of heart failure in the field of non-communicable diseases in comparison with standard care can play an important role in informing decision makers about reimbursement of costs, pricing of medical interventions, providing clinical guidelines Cost-effective use of next-generation drugs, targeted interventions, and the production of scientific evidence to make policy decisions will ultimately lead to cost management, efficiency, and optimal allocation of the health system's limited financial resources in the field of cardiovascular disease economics. Given the high burden of cardiovascular disease, limited financial resources in different countries and the share of their GDP in the health system, conduct more comprehensive studies to eliminate these differences in analysis due to limited resources. It seems necessary to introduce a dominant option in the field of economic evaluation based on studies conducted worldwide. Therefore, the present study systematically reviews the economic evaluation of Ivabradine in comparison with other common treatments, focusing on patients with heart failure.
Heart failure is one of the most common cardiovascular disorders and is considered as a chronic, progressive and debilitating disorder. Its prevalence increases with age, so that in the United States, about one percent of people over the age of 50 and about ten percent of the elderly over the age of 80 have heart failure. On the other hand, progress in treatment and surgery has caused patients who survive death from myocardial infarction to subsequently develop heart failure (3) Increasing trend of heart failure due to complications of infectious, inflammatory, vascular and valvular diseases Heart disease is also a major health problem and an epidemic in the United States, with 5 million people with heart failure in the United States, and about 500,000 new cases are added each year, and are expected in the next 30 years. Double the existing statistics (4) Research shows that the quality of life of heart failure patients is lower than the general population and also compared to other chronic patients. (5)
The US Food and Drug Administration (FDA) approved Corlanor, a generic drug called Ivabradine, in 2015 to reduce the severity of heart failure (chronic heart failure) in 2015. It is used in patients with symptoms of persistent heart failure (normal heart rate is at least 70 beats per minute).
Cost-effectiveness analysis of Ivabradine as a new strategy in the treatment of heart failure in the field of non-communicable diseases in comparison with standard care can play an important role in informing decision makers about reimbursement of costs, pricing of medical interventions, providing clinical guidelines Cost-effective use of next-generation drugs, targeted interventions, and the production of scientific evidence to make policy decisions will ultimately lead to cost management, efficiency, and optimal allocation of the health system's limited financial resources in the field of cardiovascular disease economics. Given the high burden of cardiovascular disease, limited financial resources in different countries and the share of their GDP in the health system, conduct more comprehensive studies to eliminate these differences in analysis due to limited resources. It seems necessary to introduce a dominant option in the field of economic evaluation based on studies conducted worldwide. Therefore, the present study systematically reviews the economic evaluation of Ivabradine in comparison with other common treatments, focusing on patients with heart failure.
Keywords: Economic evaluation, Ivabradine, Heart failure, Standard treatment, Heart rate, Systematic review
Received: 2021/03/9 | Accepted: 2021/09/1 | Published: 2022/09/1
Send email to the proposal executer
| Rights and permissions | |
 | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
